Ignite Creation Date:
2024-05-06 @ 4:10 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04892693
Status:
RECRUITING
Last Update Posted:
2022-09-02
First Post:
2021-05-10
Brief Title:
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Sponsor:
Seoul National University Hospital
Organization:
Seoul National University Hospital
Study Overview
Official Title:
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency A Phase II Clinical and Exploratory Biomarker Study of Talazoparib
Status:
RECRUITING
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations Beyond BRCA1 and BRCA2 mutations it is plausible that talazoparib may have activity in patients with homologous recombination defects HRD
Detailed Description:
BRCA 12 plays an essential role in homologous recombination repair and breast cancer patients with BRCA 12 germline mutation have homologous recombination defects HRD Besides BRCA1 or BRCA2 germline mutation a proportion of breast cancer is characterized as having HRD through germline mutation somatic mutation and epigenetic alteration of other homologous recombination repair HRR genes which includes but are not limited to ATM BARD1 BRIP1 CDK12 CHEK1 CHEK2 FANCL PALB2 PPP2R2A RAD51B RAD51C RAD51D and RAD54L 5 It is speculated that tumor with HRD may have clinical benefit from PARP inhibitor However the efficacy of talazoparib in advanced breast cancer with HRD is not known The primary purpose of the present study is to evaluate the efficacy of talazoparib in breast cancer with HRD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None